- Home
- MESO
MESO
Mesoblast Limited
as 11-21-2024 11:36am EST
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
| Founded: | 2004 | Country: | Australia |
| Employees: | N/A | City: | N/A |
| Market Cap: | 1.1B | IPO Year: | N/A |
| Target Price: | $11.50 | AVG Volume (30 days): | 214.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.61 - $12.18 | Next Earning Date: | 08-28-2024 |
| Revenue: | $5,902,000 | Revenue Growth: | -21.32% |
| Revenue Growth (this year): | 66.05% | Revenue Growth (next year): | 348.27% |
Latest Mesoblast Limited News
MESO Breaking Stock News: Dive into MESO Ticker-Specific Updates for Smart Investing
TipRanks
7 days ago
Mesoblast Issues 2 Million Warrants for Strategic Flexibility
Simply Wall St.
14 days ago
ASX Growth Companies With High Insider Ownership Seeing Up To 61% Earnings Growth
Simply Wall St.
16 days ago
Three High Growth Tech Stocks in Australia
GlobeNewswire
22 days ago
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024
Simply Wall St.
22 days ago
When Will Mesoblast Limited (ASX:MSB) Become Profitable?
TipRanks
a month ago
Mesoblast Advances Cellular Medicines Amid FDA Hopes
Simply Wall St.
a month ago
ASX Growth Companies With High Insider Ownership In October 2024
Simply Wall St.
a month ago
3 ASX Growth Companies With Insider Ownership Up To 37%
Compare MESO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MESO Mesoblast Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.